You swab a sample, mail it off, and three weeks later you get a report telling you your gut age is 47, you have "low Akkermansia," and you should eat more polyphenols. Is any of that actionable? And which of the half-dozen microbiome tests on the market actually gives you something useful?
The short answer: it depends on what you're testing and what you plan to do with the results. Microbiome testing is genuinely interesting technology, but the gap between what the marketing promises and what the science currently supports is wide. Here's how to navigate it.
Gut microbiome testing is an evolving field. Reference ranges and clinical interpretations vary significantly between labs. Treat results as directional signals, not diagnoses. No microbiome test can tell you what is causing your symptoms.
What These Tests Actually Measure
All consumer gut microbiome tests start by extracting DNA from your stool sample. What happens next depends on the technology the company uses, and this is where the differences that matter begin.
16S rRNA Sequencing
This is the most common approach. It targets a specific region of the bacterial ribosomal gene that acts as a fingerprint. The upside: it's relatively cheap and can identify most bacterial genera. The downside: it reads a fragment, not the full genome. This means it can tell you "there is a Bifidobacterium here" but often can't distinguish between species. Given that species-level differences within the same genus can be medically significant, this is a real limitation.
Most consumer-grade tests — including early versions of Ombre (now Viome) — used 16S sequencing. It's useful for getting a rough map of your microbial landscape, but don't mistake genus-level data for clinical precision.
Shotgun Metagenomics
This approach sequences everything in the sample — all DNA from all organisms, including fungi, viruses, and non-bacterial microbes. It provides species-level and sometimes strain-level resolution, and can also identify what your bacteria are doing (their functional capacity), not just who's there.
The tradeoff: it's significantly more expensive, computationally intensive, and generates so much data that interpretation is harder. The reference databases for comparing your results to "healthy" populations are also still being built — we don't have consensus on what a "good" microbiome looks like.
GI-MAP uses real-time PCR (polymerase chain reaction) targeting specific pathogens, bacteria, and markers — it's less of a landscape survey and more of a targeted clinical panel ordered by functional medicine practitioners.
Related: Our Biological Age Calculator can help you apply these ideas. For the complete picture, see our Men's Health Optimization by Decade.
A Comparison of the Main Options
Viome uses what it calls "metatranscriptomic sequencing" — it sequences active RNA, not just DNA. The argument is that this tells you which bacteria are metabolically active, not just present. The reports include food and supplement recommendations specific to your results. The interpretation layer is algorithmic and proprietary, which makes it hard to evaluate independently.
Cost: ~$199–$399. Best for: people who want personalized supplement/food recommendations and don't mind algorithm-driven guidance.
Ombre (previously Thryve) uses 16S sequencing and pairs results with personalized probiotic recommendations. The interface is consumer-friendly. The science underpinning the probiotic matching is not peer-reviewed.
Cost: ~$99–$149. Best for: entry-level curiosity; limited clinical depth.
GI-MAP is a clinical-grade stool test ordered through practitioners. It quantifies specific pathogens (H. pylori, C. diff, parasites), measures markers like secretory IgA and calprotectin (useful inflammation markers), and identifies bacterial overgrowths. It doesn't give you a microbiome diversity profile, but what it does measure is clinically interpretable.
Cost: ~$350+ usually through a functional medicine practitioner. Best for: people with GI symptoms — bloating, irregular bowel habits, unexplained fatigue — who want actionable clinical data.
Pros
- +Shotgun metagenomics provides species-level resolution — more nuanced than 16S
- +GI-MAP can identify pathogens and inflammation markers that standard tests miss
- +Testing before and after a gut protocol gives you measurable before/after data
- +Some markers (calprotectin, secretory IgA) have well-established clinical relevance
- +Repeat testing over time can track directional changes in microbiome diversity
Cons
- -No consensus on what a 'healthy' microbiome actually looks like — reference ranges vary widely
- -16S sequencing can't reliably distinguish between bacterial species, limiting clinical value
- -Single-sample tests miss day-to-day and week-to-week variation in microbiome composition
- -Proprietary algorithms behind most consumer products can't be independently verified
- -Most consumer-grade results don't map to evidence-based interventions
The Actionability Problem
Here's the uncomfortable truth about most consumer microbiome reports: the recommendations they generate (eat more fiber, try this probiotic, reduce stress) are nearly identical to general gut health advice that applies to everyone regardless of their microbiome composition.
The field is not yet at a point where knowing your specific bacterial ratios reliably tells you which intervention will work for you specifically. The interventions with the strongest evidence for improving gut health — dietary fiber diversity, fermented foods, reducing ultra-processed food intake, exercise, sleep — are universal, not individualized.
Where testing does add value: if you have persistent GI symptoms and standard testing has come back negative, a GI-MAP or similar clinical panel may surface actionable findings (H. pylori, parasites, calprotectin elevation) that guide treatment options.
Be the first to try Prova
We're building an app to track whether gut health actually works. Join the waitlist.
How to Track Whether Gut Interventions Are Working
The practical limitation of microbiome testing for self-experimenters is the cost of repeat testing. A more tractable approach: define proxy metrics you can track daily without a lab.
Useful daily markers that may reflect gut health changes:
- Stool consistency (Bristol Stool Scale 3–4 is the target)
- Bloating frequency and severity (0–10 scale, logged daily)
- Energy levels, particularly post-meal energy crashes
- Sleep quality scores from your wearable
Run a baseline period of 2 weeks logging these metrics before starting any gut protocol. Then track through the intervention. If you want a microbiome snapshot at baseline and after 60 days, GI-MAP is the most clinically actionable option for people with symptoms; Viome is adequate for curiosity-driven tracking in people without symptoms.